Pharvaris (NASDAQ:PHVS - Get Free Report) reached a new 52-week low during mid-day trading on Thursday . The stock traded as low as $14.50 and last traded at $14.99, with a volume of 152659 shares. The stock had previously closed at $15.45.
Wall Street Analysts Forecast Growth
Separately, JMP Securities upped their target price on shares of Pharvaris from $46.00 to $55.00 and gave the stock a "market outperform" rating in a research note on Friday, January 31st.
Read Our Latest Stock Report on PHVS
Pharvaris Stock Performance
The stock has a market cap of $784.87 million, a P/E ratio of -5.36 and a beta of -3.02. The company's 50 day moving average price is $17.40 and its 200-day moving average price is $19.19.
Institutional Trading of Pharvaris
Several institutional investors have recently made changes to their positions in PHVS. Public Employees Retirement System of Ohio bought a new position in Pharvaris during the third quarter valued at about $57,000. JPMorgan Chase & Co. grew its position in Pharvaris by 1,125.3% during the fourth quarter. JPMorgan Chase & Co. now owns 3,100 shares of the company's stock valued at $59,000 after buying an additional 2,847 shares during the period. Cubist Systematic Strategies LLC bought a new position in Pharvaris during the fourth quarter valued at about $64,000. Barclays PLC bought a new position in Pharvaris during the third quarter valued at about $106,000. Finally, KLP Kapitalforvaltning AS bought a new position in Pharvaris during the fourth quarter valued at about $111,000.
Pharvaris Company Profile
(
Get Free Report)
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.
Recommended Stories
Before you consider Pharvaris, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pharvaris wasn't on the list.
While Pharvaris currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for April 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
